NorthCrest Asset Manangement LLC Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

NorthCrest Asset Manangement LLC bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 21,687 shares of the biotechnology company's stock, valued at approximately $430,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ADMA. B Group Inc. purchased a new stake in shares of ADMA Biologics in the 4th quarter worth about $39,231,000. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics in the 4th quarter worth about $19,076,000. Arrowstreet Capital Limited Partnership lifted its position in shares of ADMA Biologics by 57.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock worth $47,380,000 after purchasing an additional 1,013,456 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after purchasing an additional 643,661 shares during the period. Finally, Man Group plc lifted its position in shares of ADMA Biologics by 305.5% in the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock worth $12,782,000 after purchasing an additional 561,507 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. Raymond James lifted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.

Insiders Place Their Bets

In related news, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director now directly owns 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 7,779 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total transaction of $158,069.28. Following the sale, the director now owns 114,830 shares of the company's stock, valued at $2,333,345.60. This trade represents a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,000 shares of company stock valued at $814,936. Insiders own 3.50% of the company's stock.

ADMA Biologics Stock Down 3.7%

Shares of ADMA Biologics stock opened at $20.81 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market capitalization of $4.97 billion, a PE ratio of 74.32 and a beta of 0.47. ADMA Biologics, Inc. has a 52-week low of $10.21 and a 52-week high of $25.67. The company has a 50-day simple moving average of $20.94 and a two-hundred day simple moving average of $18.83.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm's quarterly revenue was up 40.2% on a year-over-year basis. During the same period last year, the firm posted $0.08 earnings per share. On average, analysts anticipate that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.